Cogent Biosciences (COGT) revenue and earnings history
Cogent Biosciences's annual figures for 9 fiscal years, as filed with the SEC.
Over 3 years, from fiscal 2017 to fiscal 2020, revenue grew at a compound rate of −2.0% a year.
Revenue and net income, 9 fiscal years
Annual figures, newest first
| Fiscal year | Revenue | Operating income | Net income | Operating cash flow | Capital expenditure | Free cash flow | Stock-based pay | Share buybacks | Dividends paid | Cash at year end | Total debt at year end | Report |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025ended Dec 31, 2025 | — | −$333M | −$329M | −$264M | $1.55M | −$266M | $46.1M | — | — | $312M | $223M | 10-K |
| 2024ended Dec 31, 2024 | — |
The latest quarter, insider trades and fund moves: Cogent Biosciences (COGT) on OQRO.
Common questions
How fast has Cogent Biosciences's revenue grown?
From $8.36M in fiscal 2017 to $7.87M in fiscal 2020: a compound annual growth rate of −2.0% over 3 years. This is arithmetic on the filed figures and says nothing about the years ahead.
Has Cogent Biosciences been profitable?
It reported a net loss in 9 of the years shown (2017, 2018, 2019, 2020, 2021, 2022, 2023, 2024, 2025). The highest net income was −$25.5M in fiscal 2017.
What was Cogent Biosciences's free cash flow in fiscal 2025?
−$266M: operating cash flow of −$264M minus capital expenditure of $1.55M. OQRO calculates free cash flow this way from the two filed lines.
Where these figures come from
The SEC’s companyfacts data: every figure Cogent Biosciences tagged in XBRL in its annual and quarterly reports since 2009 (some reports carry a few earlier years as comparatives). For each fiscal year OQRO keeps the twelve-month totals from the annual report and the cash and debt at year end, and when a later report restates a year, the later figure. Read again whenever the company files.
Figures are as reported, in US dollars, with no adjustment for acquisitions, disposals or one-off items. Earnings per share are left out because a stock split changes them between reports. This page describes the past and is not investment advice. No language model wrote it.
